Background and Objectives Methadone is a l-opioid agonist widely used for the treatment of pain, and for detoxification or maintenance treatment in opioid addiction. It has been shown to exhibit large pharmacokinetic variability and concentration-QTc relationships. In this study we investigated the relative influence of genetic polymorphism and other variables on the dose concentration-QTc relationship. Patients and Methods A population model for methadone enantiomers in 251 opioid-dependent patients was developed using non-linear mixed effect modeling (NONMEM Ò ). Various models were tested to characterize the pharmacokinetics of (R)-and (S)-methadone and the pharmacokinetic-pharmacodynamic relationship, while including demographics, physiological conditions, comedications, and genetic variants as covariates. Modelbased simulations were performed to assess the relative increase in QTc with dose upon stratification according to genetic polymorphisms involved in methadone disposition. Results A two-compartment model with first-order absorption and lag time provided the best model fit for (R)-and (S)-methadone pharmacokinetics. (S)-methadone clearance was influenced by cytochrome P450 (CYP) 2B6 activity, ABCB1 3435C[T, and a-1 acid glycoprotein level, while (R)-methadone clearance was influenced by CYP2B6 activity, POR*28, and CYP3A4*22. A linear model described the methadone concentration-QTc relationship, with a mean QTc increase of 9.9 ms and 19.2 ms per 1000 ng/ml of (R)-and (S)-methadone, respectively. Simulations with different methadone doses up to 240 mg/day showed that \8 % of patients presented with a QTc interval above 450 ms; however, this might reach 12 to 18 % for (R)-and (S)-methadone, respectively, in patients with a genetic status associated with a decreased methadone elimination at doses exceeding 240 mg/day. Conclusion Risk factor assessment, electrocardiogram monitoring, and therapeutic drug monitoring are beneficial to optimize treatment in methadone patients, especially for those who have low levels despite high methadone doses, or who are at risk of overdosing.
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Introduction
Methadone is a l-opioid agonist that has been used for more than 30 years for the treatment of pain, and for detoxification or maintenance treatment in opioid addiction. In 2005, the World Health Organization introduced this drug in the list of essential medicines [1] . However, there are numerous case reports, retrospective analyses, and observational studies describing QT prolongation and torsade de pointes (TdP) in patients receiving methadone treatment, especially in those receiving high to very high doses of methadone [2] .
Methadone is mainly administered as a chiral mixture of (R,S)-methadone. However, l-opioid receptor activation is mostly due to (R)-methadone [3] , while (S)-methadone is 3.5-fold more potent in blocking the cardiac human ethera-go-go-related gene (hERG) channel, with the latter therefore being at higher risk for prolonging the QT interval [4, 5] . The higher potential of the (S)-enantiomer blocking the hERG channel was confirmed in opioid-dependent patients receiving maintenance treatment in whom replacement of (R,S)-methadone by (R)-methadone led to a significant decrease in QT c values [6] . Nonetheless, as (R)-methadone is currently available in only a few countries, the prescription of (R,S)-methadone should in no way be limited when clinically indicated and well monitored.
Variability in the methadone concentration and effect relationship is very large. Pharmacokinetic variability has been attributed to cytochrome P450 (CYP) isoenzymes, mainly CYP3A4 and CYP2B6, and to P-glycoprotein (P-gp; encoded by the ATP-binding cassette subfamily B member 1 [ABCB1] gene), the activities of which are genetically and environmentally determined [7] . In addition, stereoselective CYP2B6-mediated metabolism of (S)-methadone, as evidenced by previous in vitro/in vivo data [8] [9] [10] [11] , induces higher plasma concentrations of (S)-methadone than (R)-methadone in CYP2B6 slow metabolizers [12, 13] . The CYP2B6*6/*6 genotype represents approximately 6 % of Caucasians and African Americans, who could thus be at higher risk of developing cardiotoxicity. CYP reductase (POR) plays a major role in drug metabolism as all microsomal CYPs receive electrons from nicotinamide adenine dinucleotide phosphate (NADPH) through POR [14] . A large number of POR SNPs have now been described, which might influence CYP activities and thus drug metabolism [14] . Although stereoselective pharmacokinetics of methadone, genetic influences on (R)-and (S)-methadone concentration, and concentration-effect relationships have been already explored [15] [16] [17] , the relative influence of genetic polymorphism and other variables on the dose-concentration-QTc relationship remains to be investigated.
The objectives of this study were to characterize the population pharmacokinetics of (R)-and (S)-methadone, identify genetic and non-genetic sources of variability, and relate methadone concentrations to QTc interval in a cohort of opioid-dependent patients receiving methadone maintenance treatment. The model served to simulate the (R)-and (S)-methadone concentration-QTc interval relationship at various dose regimens of methadone, according to the genetic status, in order to quantify the expected increase of QTc in the different groups.
Materials and Methods

Study Population
Plasma (R)-and (S)-methadone levels, measured by liquid chromatography coupled with mass spectroscopy [18] , and QTc measurements were obtained from 244 opioid-dependent patients in five methadone-dispensing centers in Geneva, Lausanne, Bern, and Montreux in Switzerland [7] . Steady-state concentration samples with matched QTc interval determinations (Fridericia-corrected) were collected around peak (4 h) and/or trough (24 h) drug levels. In addition, seven opioid-dependent patients taking part in an interaction study [19] provided 11 (R)-and (S)-methadone concentrations per patient, measured by liquid chromatography coupled with ultraviolet detection [20] , collected between 0.5 and 23 h post-dose under steady-state conditions. The mean (±standard deviation [SD]) methadone daily dose was 123 (±75) mg (range 3-400 mg) and was administered once or twice daily. The Ethics Committees of the corresponding centers approved the project, and all participants gave written informed consent for genetic testing.
Analytical Method
Genotyping
Genomic DNA was extracted from EDTA blood samples using the FlexiGene DNA Kit (Qiagen, Hombrechtikon, Switzerland). All SNPs, with the exception of CYP2D6*5, CYP2D6*xN and CYP3A4*22, were detected by real-time polymerase chain reaction (PCR) with the use of 5 0 -nuclease allelic discrimination assays (ABI PRISM 7000 Sequence Detection System; Applied Biosystems, Rotkreuz, Switzerland), with primers and probes obtained from Applied Biosystems. The tested genetic polymorphisms are listed in Table 2 and were analyzed as previously described, with the exception of CYP3A4*22 [7, [21] [22] [23] , which was genotyped with a custom Illumina iSelect genotyping array on an iScan-equipped platform (Illumina, Inc., San Diego, CA, USA). Quality control was assessed by the call rate ([96 %), gene call (GC) score ([0.15), and matched sex. Genetic data were extracted by using GenomeStudio software, version 2011.1 (Illumina, Inc.).
Model-Based Pharmacokinetic Modeling
The model-building process consisted of (i) a population pharmacokinetic model for (R)-and (S)-methadone using rich sampling data; (ii) an extension to the whole dataset while taking into account potential influencing variables; and (iii) a simultaneous pharmacokinetic-pharmacodynamic analysis for the concentration-QTc interval relationship evaluation.
Structural Models
A stepwise procedure was used to find the models that best fitted methadone data. The final pharmacokinetic model was a two-compartment model with first-order absorption and lag time for both drugs. The estimated parameters were clearance (CL), volume of distribution of the central compartment (V c ), volume of distribution of the peripheral compartment (V p ), intercompartmental clearance (Q), absorption rate constant (k a ), and lag-time (T lag ). Since methadone was only administered orally, CL, V c , V p , and Q represent apparent values. Methadone was administered as a racemic mixture composed of a 50:50 mix of both enantiomers. In addition, methadone dose was reduced by half by fixing the relative bioavailability to 0.5 for the separate analysis of each moiety. Exponential errors following a log-normal distribution with mean zero and variance x 2 were assumed for the description of the interindividual variability. A proportional error model was used to model the residual variability, with mean zero and variance R 2 . Methadone elimination half-lives (t a and t k), volume of distribution at steady state (Vd ss ), and mean absorption time (MAT = 1/k a ? lag time) were derived using classical equations.
Covariate Models
The available covariates were demographics (sex, body weight, race), physiopathological (a1-glycoprotein, albumin), environmental (smoking, co-medications) ( Table 1) , and tested genetic polymorphisms ( Table 2 ). The potential influence of available covariates were explored graphically and were then tested for significance into the model. The typical value of a parameter was modeled to depend on a covariate (continuous variables centered on the mean; categorical covariates being coded as indicator variables 0 or 1), testing linear and non-linear relationships, as appropriate. Co-medications were classified into inducers or inhibitors of CYP3A4 and CYP2B6, and inhibitors of CYP2D6 [24] [25] [26] [27] (Table 1) . Co-medications potentially affecting the QT intervals were categorized as drugs with a known, possible, or conditional risk of TdP according to CredibleMeds.org [28] , and patients were grouped according to their highest risk co-medication. Genetic variants were classified into three groups: reference allele (Ref), heterozygote (Het) loss/decrease/gain of function (LOF/DOF/GOF), and homozygote (Hom) LOF/DOF/GOF variants. LOF and DOF alleles will be defined as DOF hereafter. An activity score for CYP2B6 was derived to test for the effect of a combination of CYP2B6*6, *5 and *11 alleles. In this model, a score of 2 was attributed to fully functional alleles CYP2B6*1/1, *5/*5, *1/*4, *1/*5, and *4/*5; a score of 1 to CYP2B6*1/*11, *1/*6, *4/*6, and *5/*6; and a score of 0 to CYP2B6*6/*6 and *6/*11. The relationship between methadone CL and the number of functional alleles was first tested using a rich model (Eq. 1) and competing models that accounted for gene effect as a function of the number of functional alleles using linear (Eq. 2), power (Eq. 3), and square root (Eq. 4) relationships with either additive or proportional (not shown) effect, as follows: 
where CL 0 is CL in the individuals' Hom DOF for both genes, and I ij is an indicator variable that takes the value of 1 if the individual carries the CYP2B6 ith genotype and the ABCB1 3435C[T jth genotype, and is '0' otherwise, and SD standard deviation, BMI body mass index, bpm beats per min, AST aspartate aminotransferase, ALT alanine aminotransferase, c-GT gamma glutamyltransferase, CYP cytochrome P450, PK pharmacokinetics, TdP torsade de pointes a CYP3A4 strong inhibitor: nefadozone (n = 1); CYP3A4 weak inhibitors: efavirenz (n = 2), fluoxetine (n = 10), fluvoxamine (n = 3), quetiapine (n = 8), valproate (n = 6), desogestrel and/or ethinylestradiol (n = 2); CYP3A4 and CYP2B6 strong inducers: carbamazepine (n = 1), efavirenz (n = 2), St John's wort (n = 1); CYP3A4 weak inducers: topiramate (n = 10); CYP2B6 weak inhibitors: efavirenz (n = 2); CYP2D6 strong inhibitors: bupropion (n = 1), fluoxetine (n = 10), paroxetine (n = 10), levomepromazine (n = 5), metoclopramide (n = 2), thioridazine (n = 4); CYP2D6 weak inhibitors:
, haloperidol and astemizole (n = 1), escitalopram and thioridazine (n = 1); possible risk: mirtazapine (n = 26), olanzapine (n = 10), quetiapine (n = 5), mirtazapine and olanzapine (n = 4), risperidone (n = 3), venlafaxine (n = 3), mirtazapine and quetiapine (n = 2), aripiprazole (n = 1), trimipramine (n = 1), tizanidine (n = 1), mirtazapine and venlafaxine (n = 1); conditional risk: fluoxetine (n = 7), paroxetine (n = 6), chloral hydrate (n = 4), sertraline (n = 3), amisulpride (n = 2), paroxétine and pantoprazole (n = 2), doxepine (n = 1), fluoxetine and chloral hydrate (n = 1), paroxetine and chloral hydrate (n = 1) each h ij estimate is the absolute change in CL among the different genotypic groups. The following competing models were evaluated:
where p indicates the functional score for CYP2B6 and q indicates the score for ABCB1 3435C[T. In Eq. 6, the contribution of ABCB1 3435C[T (h 2 , h 3 ) is investigated using all genetic groups on CYP2B6 polymorphism, and in reduced models and testing linear (Eq. 7) and square root functions (Eq. 8) for both genes.
Concentration-QTc Modeling
The relationship between methadone concentrations and the Fridericia heart-rate corrected QT c [29] interval were explored using linear and log-linear models of the general form:
where Slope i and Intercept i are the slope and the intercept for the ith individual, QTc ij is the Fridericia's corrected QT interval, and Conc ij is the methadone concentration for the ith individual and the jth time point. The residual variability, e ij , was included assuming an additive error with mean zero and variance R 2 , and an interindividual variability on the slope and intercept was tested assuming a normal distribution with mean zero and variance x 2 . Factors potentially influencing the QTc interval were sex, potassium and calcium levels, and these were included in the model using linear functions. Co-medications known to influence the QTc interval were included in the models as dichotomous variables.
Parameter Estimation and Selection
NONMEM
Ò [30] (version 7.2, NM-TRAN, version II) was used with the first-order conditional estimation (FOCE) interaction method to fit the data. The minimum objective c Effect might be substrate-dependent function value (DOF) provided by NONMEM Ò , (-2 log likelihood, approximate Chi-square distribution) was used to discriminate between hierarchical models using the loglikelihood test. A model was considered superior to another nested model when the OFV value was reduced by at least 3.84 points (p \ 0.05). Covariate analysis comprised forward selection of influential factors followed by backward deletion, and were retained in the final model at the statistical level of p \ 0.01. The most appropriate model for the concentration-QTc relationship was selected based on Akaike information criteria and the log-likelihood test for the influence of covariates. Model assessment was based on diagnostic plots, along with the measure of the standard errors, the correlation matrix of parameter estimates, the size of residual errors, and eta-shrinkage.
Model Validation
The stability and performance of the final population pharmacokinetic model were validated by the bootstrap method using 2000 bootstrap resampling with replacement (Perl Speaks NONMEM version 3.2.4 [http://psn.sourceforge.net/ ]). The median and 95 % confidence interval (CI) of each parameter obtained with the bootstrapped data were compared with the parameters of the original dataset. In addition, simulations were performed in 1000 individuals to predict the 2.5th, 50th and 97.5th percentiles of the concentrations and QTc intervals and compared with observed data. The figures were generated using GraphPad Prism, version 4.00 for Windows (GraphPad Software, San Diego, CA, USA; www.graphpad.com).
Simulations
Simulations for (R)-and (S)-methadone plasma and QT intervals were performed in 1000 individuals for doses ranging from 80 to 280 mg once daily at steady state. The volume of distribution of (S)-methadone was fixed for a typical patient, with a median a-1 acid glycoprotein (AAG) level of 0.97 g/l. The 'lowest' CL and 'best' CL values were calculated for (R)-and (S)-methadone, stratified according to genetic status. Average QT interval predictions with the 95 % prediction intervals (PI 95 % ) for each dose regimen were retrieved. In addition, the percentage of patients with absolute QT above the thresholds of [450 and [470 ms associated with an increased risk of cardiotoxicity was derived.
Prediction of the (R,S)-Methadone Plasma Concentration Threshold for QTc Prolongation Risk
Receiver operating characteristic (ROC) analyses and graphs were performed using GraphPad Prism, version 6.05 for Windows (GraphPad Software) to predict a threshold of (R,S)-methadone plasma concentrations for increased risk of QTc above 450 ms.
Results
A total of 50507 (R)-and (S)-methadone plasma concentrations and 317 QTc intervals were used for the analysis. A summary of the population characteristics and the tested genetic polymorphisms are presented in Tables 1 and 2 .
Population Pharmacokinetic Analysis
Structural Model for (R)-and (S)-Methadone
Analyses from seven individuals with rich sampling showed that a two-compartment model with first-order absorption fitted the data better than a one-compartment model for both enantiomers (DOF \ -23; p \ 0.001); the addition of a lag time significantly improved the fit for both compounds (DOF \ -34; p \ 0.001). In addition to CL, assignment of an interindividual variability on K a improved the fit for (R)-methadone (DOF = -43; p \ 0.001) and (S)-methadone (DOF = -37; p \ 0.001), as well as on Q for the latter (DOF = -7; p \ 0.01). This model adequately fitted (R)-and (S)-methadone concentrations of the whole population. The lack of drug level measurements during the absorption phase prevented a precise estimation of K a ; thus, this parameter and the lag time were fixed to the estimates from the rich data analysis. The addition of an interindividual variability on V c and Q (DOF \ -34; p \ 0.001) improved the description of the data of both enantiomers, with a correlation between CL and V c (DOF \ -12; p \ 0.01). Allowing K a and V p to vary did not improve the model fit (DOF [ -1.2).
Covariate Modeling on (S)-Methadone
Among the non-genetic covariates, only AAG concentrations influenced V c (DOF = -12.8; p \ 0.001), indicating a 25 % increase in volume upon AAG doubling. Univariate analyses testing the influence of genetic polymorphisms revealed that CYP2B6*6 had a marked impact on (S)-methadone elimination (DOF = -14.0; p \ 0.001), with an estimated CL of 10.6, 9, and 6.6 l/h in Ref, Het DOF allele, and Hom DOF patients, respectively. A trend for an influence of the CYP2B6 rs2279344 polymorphism was found (DOF = -3.8; p = 0.051), suggesting a 14 % decrease in (S)-methadone CL in Hom DOF carriers compared with the other groups. CYP2B6*11 (DOF = -2.4; p = 0.12) and CYP2B6*5 (DOF = -0.7; p = 0.4) did not show any influence. The use of an activity score combining CYP2B6*6, *5, and *11 improved the fit (DOF = -20.4; p \ 0.001), providing very close estimates of CL to the model solely including CYP2B6*6, and was retained for further analyses. The relationship between CL and the number of CYP2B6 functional alleles could adequately be described by a square root model (Eq. 4). This model estimated a CL of 6.2 L/h in Hom DOF patients that increased by 3:1 Á p n (n = number of functional allele). Polymorphism in POR*28 showed a significant influence on CL (DOF = Stepwise inclusion of the significant genetic variants in the multivariate analyses identified CYP2B6 activity score and ABCB1 3435C[T polymorphism as significant covariates on CL. Both allele influences were best captured using a square root model for CYP2B6 functional alleles, with an additional influence of ABCB1 3435C[T for Hom DOF carriers of this gene (Eq. 6). No statistical difference in CL between ABCB1 3435C[T Het DOF and Hom DOF stratified for CYP2B6 was observed, and both linear (Eq. 7) and square root models (Eq. 8) also described the data (DOF [ -0.7). All other significant allelic variants were correlated to both genes and did not remain statistically significant. The influence of AAG levels on V c was retained in the final model. This final model explained 4, 16, and 7 % of the interindividual variability on CL, V c, and Q, respectively.
Covariate Modeling on (R)-Methadone
No non-genetic factors showed any influence on (R)-methadone disposition. Inclusion of CYP2B6*6 (DOF = -7.0; p \ 0.01) and CYP2B6 activity score (DOF = -7.5; p \ 0.01) improved the description of (R)-methadone elimination. These models estimated a CL of 10.4, 9. The CYP2B6 activity score, POR*28 and CYP3A4*22 remained statistically significant in the multivariate analysis. CYP2B6 rs8192719 was not retained due to a strong linkage with CYP2B6*6. The joint effect of the three alleles was best fitted using an additive model (Eq. 6), with no further improvement while using competing models (Eqs. 7 or 8). This final model explained 5, 6, and 16 % of the interindividual variability on CL, V c , and Q, respectively.
Methadone Concentration-QTc Interval Analysis
The concentration-QT c interval relationship was fitted using a linear model, with no difference observed using a log-linear model (DOF \ -1.83). The assignment of an interindividual variability on the intercept parameter significantly improved the fit (DOF = -62 for (R)-methadone, and DOF = -64 for (S)-methadone; p \ 0.001), but no variability on the slope parameter was found (DOF = 0). A slightly non-significant higher intercept QTc level of approximately 3 ms was observed in women compared with men, and no difference in slope was observed (DOF [ -2). Neither potassium nor calcium levels significantly influenced the concentration-QTc relationship (DOF [ -1.3), nor did co-medications at risk of QTc prolongation. The final population parameters are presented in Table 3 , and goodness-of-fit plots are presented in electronic supplementary Fig. 1 .
Model Validation
The median parameter estimates obtained with bootstrap, with the 95 % CI, are presented in Table 3 . The parameter estimates of the final population pharmacokinetic model lay within the 95 % CI of the bootstrap results, suggesting that the model was acceptable. The visual predictive check of the observed methadone concentrations versus time, as well as the concentration-QTc plots, are shown in Fig. 1 .
Simulations
Simulations of (R)-and (S)-methadone concentrations for 80-320 mg once daily, assuming a 'best' and 'lowest' elimination of each enantiomer according to influencing genetic effects, are shown in Fig. 2 . The probability of the QT C value being above the 450 ms threshold is increased by 1.5-to 2-fold, depending on the genotypic status. Less than 4 % of patients would present a QTc value above 450 ms at the dose levels below or equal to 160 mg daily, but this number might increase up to 10 % for patients at doses exceeding 240 mg/day with a genetic status associated with a decreased methadone elimination, particularly observed for (S)-methadone. According to our model, less than 1 % of patients would present QTc values above 470 ms. 
Prediction of (R,S)-methadone plasma concentration threshold for QTc prolongation risk
The ROC analysis indicates that a plasma concentration of (R,S)-methadone above 656 ng/ml is the best predictor for a QTc above 450 ms (electronic supplementary Fig. 2 ; sensitivity = 79 %; specificity = 68 %; ROC AUC = 0.69 ± 0.06; 95 %CI = 0.57-0.81, p = 0.01).
Discussion
We developed a population pharmacokinetic-pharmacodynamic model for methadone in a cohort of opioid patients, and were able to quantify the relative contribution of genetic and non-genetic factors affecting drug disposition, its consequences on the QTc interval, and predict QTc increase according to dose and patients' genetic status. Estimates of (R)-and (S)-methadone pharmacokinetic parameters are in accordance with previous results [16, 17] . No demographic covariates showed any influence on the kinetics of these compounds, except for an influence of AAG on the volume of distribution of (S)-methadone. The lack of influence of protein binding on (R)-methadone could be related to a lower protein binding of this enantiomer [31] . As expected, a marked interindividual variability in methadone pharmacokinetics was observed, and was even more pronounced for (S)-methadone. This large variability is typical of drugs that are metabolized by polymorphic enzymes such as CYP3A4 and CYP2B6. Few strongly interacting co-medications were taken by patients, thus reducing the power to detect any influence of comedications. Since CYP2D6 seems to be only moderately involved in the methadone metabolic pathway [7, 32] , an influence of CYP2D6 inhibitors was not expected.
A genetic influence of CYP2B6*6 was observed on both enantiomers, with a more important effect on (S)-methadone. Its CL is reduced by 37 % in CYP2B6 Hom DOF carriers, whereas (R)-methadone CL is decreased by 21 %. These data confirm the previously reported stereoselectivity of the CYP2B6 isoform for (S)-methadone [8, 10-13, 17, 33] . The lack of influence of CYP2B6*11 could be explained by its low minor allele frequency (0.8 %). CYP2B6*5 was also not found to influence methadone elimination, in agreement with an in vitro moderately decreased activity [33] , despite the recent finding of its overrepresentation in a group of patients with low methadone concentration (thus suggesting increased CYP2B6 activity) [22] . We therefore defined the CYP2B6 activity score by combining CYP2B6*6,*11, and *5, the major known DOF and LOF alleles of CYP2B6 in Caucasians.
In the present study, we report for the first time a decrease in methadone CL in carriers of the CYP3A4*22 allele. This variant was previously shown to affect CYP3A4 messenger RNA (mRNA) expression and enzyme activity, the mutant carriers presenting approximately 2.5-fold lower CYP3A4 activity [34] , which was verified by the CYP3A-phenotyping probes midazolam and erythromycin [35] . In univariate models, the CYP3A4*22 allele significantly decreased (R)-methadone CL (-23 %) and non-significantly decreased (S)-methadone CL (-15 %). This small difference is most likely due to the stronger influence of CYP2B6 on (S)-methadone rather than a real stereoselectivity of CYP3A4. The lack of CYP3A4 stereoselective metabolism of methadone has been previously shown in vivo [7] and in vitro [8, 10, 11] . On the other hand, CYP3A5*3 did not seem to influence either (S)-or (R)-methadone elimination, in accordance with in vitro [9] and in vivo results [7] .
An increase in the elimination of both enantiomers in POR*28 Het or Hom carriers was observed in univariate analyses, which is in accordance with the increased CYP3A activity observed by midazolam phenotyping in POR*28 Hom GOF carriers [21, 36] . Conflicting results were also found [37, 38] , which might suggest substrate-specific effects of POR variants on CYP3A activities [14] . In multivariate analyses, the influence of the POR*28 polymorphism was only observed for (R)-methadone, possibly due to the more important contribution of CYP2B6 to (S)-methadone, and thus masking the POR influence. Methadone is a substrate and inhibitor of PgP coded by the ABCB1 gene. We observed a small reduction in (S)-methadone CL in carriers of one or two DOF alleles of the gene, whereas no effect was found for (R)-methadone. These results are in agreement with an in vitro experiment suggesting a weak stereoselectivity for the transport of the (S)-enantiomer [39] . Moreover, a recent population pharmacokinetic study also found an association of ABCB1 2677G[T/A with a 20 % reduction of the CL of (R)-and (S)-methadone, but did not observe any stereoselectivity [17] .
The concentration-QTc relationship indicated that mean QTc is increased by 9.9 and 19.2 ms per 1000 ng/ml of (R)-and (S)-methadone, respectively, in line with previously reported values of 17 ms for the racemate (CI 90 % 12-22) [15] . The magnitude of the effect is small and of modest clinical relevance at a low methadone dose. The range of QTc interval measured in our population was slightly higher than in the Framingham study [40] but did not include extreme QTc values, which might explain the modest concentration-effect relationship. However, our results suggest a more pronounced QTc increase with (S)-methadone, and confirm the more potent inhibition of the hERG channel by this enantiomer [4] . Considering that the concentrations of both enantiomers can increase in patients with a geneticrelated poor elimination profile and the confirmed link between exposure and the risk of QTc prolongation, the need for caution is reinforced, especially at higher methadone doses. This need for caution has been confirmed by recent studies on drug-induced QTc prolongation. A large study on the prevalence of drug-induced long QT in adult psychiatric patients reported that prolonged QTc was significantly associated with methadone, which was the most frequent drug among patients with drug-induced long QT [41] . Furthermore, among the reported 12 cases of sudden death and/or TdP, seven patients had received methadone. In another study aimed at determining the associated factors for prolonged QTc and the development of TdP, methadone was by far the leading medication implicated in the development of TdP, and was an independent predictor in both univariate and multivariate analyses despite the fact that it was not the most common QT-prolonging medication in their population [42] .
One limitation of our study is that the relationships between both enantiomers and QTc could only be described with a linear relationship. QTc measurements were performed at two time points post-drug intake, which prevented the possibility of characterizing the full pharmacokinetic-pharmacodynamic relationship and the relative increase in QTc interval after dose administration. In this study, sex, and calcium and potassium levels did not influence QTc, and neither did co-adminstration of drugs at risk for QT prolongation. Potassium and calcium levels were in the normal range, which might have limited the detection of any association. Only a few drugs with a known risk of TdP were prescribed in this population; the influence of these drugs is expected to be modest within the normal range of QTc interval. Another limitation of our study was that other patient's risk factors, such as the use of illicit hERG blockers, were not accounted for in our model.
As previously reported [15] , a simulation approach allowed the concentration-QT interval relationship to be described, while integrating, for the first time, genetic influence on methadone elimination. Patients carrying mutation of the CYP2B6*6 are at risk of exhibiting high methadone concentrations, particularly (S)-methadone, and QTc prolongation above the 450 ms threshold. This risk is even more pronounced in cases of additional variation such as CYP3A4*22 and ABCB1 3435C[T affecting (R)-and (S)-methadone elimination, respectively. Variation in the POR*28 would only partly compensate for a CYP2B6-associated reduced (R)-methadone elimination.
The ROC analysis predicted a threshold of 656 ng/ml (R,S)-methadone plasma concentration for QTc prolongation above 450 ms. This value should be considered cautiously as only 14 values of QTc (among 317) were above 450 ms, but is close to the clinically determined threshold of 800 ng/ml previously proposed [31] .
Conclusions
Despite an important influence of CYP2B6 polymorphisms and other genes, the major part of methadone pharmacokinetic variability remains unexplained. The very large variability in plasma methadone concentrations renders the dose-concentration relationship difficult to predict. Plasma methadone concentration measurements by therapeutic drug monitoring may be beneficial to guide practitioners' dosing decisions, especially for those patients who have low levels despite high methadone doses, or who are at risk of overdosing (i.e. poor metabolizer status, high methadone dose, or suspicion of a drug-drug interaction). As previously reported, trough plasma concentrations of 250 ng/ml for (R)-methadone or 400 ng/ml for (R,S)-methadone might be used as target values in cases of non-response [31] . Due to the widely unexplained pharmacokinetic variability and the fact that pharmacodynamic pathwayrelated genes in the heart, as well as other factors such as electrolyte disturbances, may also be important, our data confirm the need for electrocardiogram monitoring and arrhythmia risk factor assessment, as determined in clinical practice for patients receiving doses above 100 or 120 mg/day [43, 44] , or for unusual situations with trough (R,S)-methadone plasma concentrations above 660-800 ng/ml [31] .
